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ABSTRACT 
Background: There is evidence that inflammation may play a role in the association between physical illness and 
depression. Our aim was to compare the impact of chronic medical conditions on incidence of depression and to 
examine if risk of depression varies in terms of the presence and degree of inflammation. 
 
Methods: This is a secondary analysis conducted within the Spanish sample of the predictD-study. Participants: 
5,437. Primary outcome: Incident major depression measured with the Composite International Diagnostic 
Interview. Exposure: Presence of chronic medical conditions recorded by GPs using the International Classification 
of Primary Care, ICPC-2. All analyses were conducted using multivariable logistic regression to allow adjustment 
for confounders. 
 
Results: The odds of depression are higher in almost all inflammatory than in non-inflammatory illnesses. There 
is an increasing risk of depression as a consequence of an increasing inflammatory load, with higher odds of 
depression in the autoimmune group than in the cardio-metabolic group, while both had higher odds of depression 
than the non-inflammatory groups.  
 
 
Conclusions: Inflammation may be part of the pathway by which chronic physical illness leads to depression. 
Future studies should examine the role of inflammation in the prevention and management of depression.  
 
Key words: Depression, inflammation, inflammatory disorders, chronic medical illnesses, major depressive 
disorder, cohort study. 
 
 
  
 
 
 
 
 
 
1. INTRODUCTION 
 
There is a large body of evidence to support a bi-directional relationship between physical illness and depression. 
Observational studies have demonstrated that people with depression have higher rates of physical illness (1,2), 
while patients with physical illness have higher rates of depression, a risk that follows a dose-response relationship 
with the number of concomitant physical illnesses (3-5). 
 
In recent years substantial evidence has emerged regarding inflammation as one explanation for the physical 
illness-depression relationship (6-8). A longitudinal study with six-year follow-up showed, in an elderly depression-
free population, that systemic inflammatory states predicted the incidence of depression, an effect that persisted 
after adjustment for physical comorbidity, subjective wellbeing, use of antidepressants, and sociodemographic 
factors(9). Studies conducted with younger populations gave similar findings. The Avon Longitudinal Study of 
Parents and Children cohort (10) showed high levels of Interleukin 6 (IL-6) at age 9 predicted the incidence of 
depression at age 18, with a dose-response relationship, even after adjustment for sociodemographic factors and 
body mass index. Nonetheless, current evidence is based upon studies that adjusted for type of illness in the 
assessment of depression risk by inflammatory markers. Hence it was not possible to analyse and compare the 
clinical diagnoses in which inflammation occurred, which is relevant for the clinical implications of such findings. 
The systemic inflammatory response can be triggered by multiple stressors, both acute and chronic, and can be 
sustained for short or long periods of time, depending upon what triggered it. Hence a different approach for 
assessing the risk of depression in those with physical illness with an inflammatory profile is both scientifically and 
clinically necessary to improve current evidence about the illness-depression relationship. 
 
The aim of this study was to explore and compare the impact of chronic medical conditions with and without an 
inflammatory profile on the incidence of depression. Our hypothesis was that chronic inflammatory illnesses confer 
  
a higher risk of depression than non-inflammatory illnesses, independently of the quality of life associated with the 
disease, in a population of primary care attendees free of depression at baseline.  
 
2. METHODS 
 
2.1. Study design 
 
This is a secondary analysis with an a priori hypothesis, conducted within the completed Spanish cohort of the 
predictD study (11,12), a cohort study with 12 months follow up to develop and validate a risk prediction algorithm 
for the onset of depression in primary care attendees. All participants in the Spanish sample accessed The Spanish 
National Health Service, which offers free access to medical care and covers 100% of the population, providing a 
representative sample of the population, with diverse economic backgrounds. The study population aged 18 to 75 
years was recruited between October 2005 and February 2006. Participants were randomly selected from those 
booked to see their family physician each day.  Between four and six attendees were selected daily. Exclusion 
criteria were inability to understand Spanish, or a diagnosis of psychosis, dementia or severe incapacitating 
physical illness. All risk factors for depression were measured at baseline (for more details see 11). 
5,442 participants formed the predictD-Spain sample (12), but 95 participants had no information about their illness 
status, and were not included in our analysis, resulting in a final sample of 5,347 participants. At baseline, 741 
patients had major depression (14% of the sample), and thus were not included in the prediction of the risk of 
depression (See Figure 1).  
The predictD-Spain study was approved by ethics committees in each Spanish province. Participants gave 
consent for using predictD data for subsequent research projects. 
 
2.2. Classification of inflammatory and non-inflammatory illnesses 
 
The main risk factor was the presence of chronic and inflammatory physical conditions. Conditions were recorded 
in the patients’ medical records by their general practitioner (GP) using the International Classification of Primary 
Care, ICPC-2 of the World Association of Family Doctors (13). There were two main comparison groups: one 
defined as having no chronic medical condition, and the other as having only non-inflammatory disorders. 
Participants with absence of any chronic physical conditions were classified as “healthy”. Thus, participants with 
  
acute, transient or non-specific physical conditions or complaints, such as influenza or sprained ankle were coded 
as healthy.  
 
 
- 2.2.1 Chronic inflammatory conditions: Defined as physical illnesses that have a chronic course and feature, 
according to the literature, systemic inflammation as part of their pathophysiology (7),(14),(15),(16),(17). This 
group includes cardiovascular illnesses, metabolic disorders and autoimmune disorders. The latter is the one 
that carries the most systemic inflammation.   
- 2.2.2. Non inflammatory conditions: Osteoarthritis, respiratory disorders, allergies, peptic ulcer and 
gastroesophageal reflux disorder, functional disorders and locomotor pain complaints. Whilst asthma and 
chronic obstructive pulmonary disease (COPD), involve inflammation, they were coded as non-inflammatory as 
there is no clear evidence of systemic inflammation, but more of a locally situated response to pro-inflammatory 
substances such as tobacco smoke or air borne pollutants (18). The same principle was used for osteoarthritis, 
a clearly inflammatory but localised disorder, with no evidence of systemic inflammation.  
- 2.2.3.Other unclassifiable disorders: Endocrine disorders were classified as a separate category because these 
disorders can involve inflammation but simultaneously hormonal alterations that independently increases the 
risk of depression. A similar criterion applied to neurological disorders, as there are other biological mechanisms 
than inflammation through which such disorders can induce or mimic depression (19). 
 
For more detail about coding see appendix table 8. 
 
 
2.3. Measurement of major depression 
 
New cases of major depression were defined according to DSM-IV criteria using the depression section of the 
Composite International Diagnostic Interview (CIDI) (20) at either the six-month or 12-month follow-ups. 
Participants with missing outcome data at both follow-up times were excluded, as well as those with one missing 
outcome data who were not depressed in the assessment they attended, as we could not be certain that they had 
not experienced depression in the period with missing data. Participants with missing outcome data at one of the 
follow-up assessments and who had depression in the non-missed assessment attended were included in the 
analysis because they fulfilled the outcome criteria of depression during the one-year follow-up period. 
  
 
2.4. Other possible explanatory variables (confounders) 
 
The confounders included in the final model were selected upon the evidence of an association with depression 
as described in predictD-study protocol (11), and also based on evidence of an association with chronic physical 
disorders, as described in the literature. To improve the precision in the estimation of the outcome, diagnoses of 
anxiety disorders and alcohol abuse were included in the adjusted model to control for comorbid psychiatric 
illnesses. Similarly, antidepressant or benzodiazepine use at baseline was included in the adjusted model to 
control for cases of treated depression.  
 
- Sociodemographic characteristics: Age, gender, marital status, educational level, employment, financial strain, 
non-Spanish nationality. 
- Psychosocial variables: Childhood experiences of physical, psychological or sexual abuse, sum of stressful life 
events in the past 6 month, experiences of discrimination for sex, age, ethnicity, appearance, disability or sexual 
orientation. 
- Psychiatric antecedents and diagnosis at baseline: Self-rated mental and physical quality of life measured with 
SF-12(24), use of psychotropic medication according to medical records (antidepressants and 
benzodiazepines), alcohol misuse measured with Alcohol Use Disorders Identification Test (AUDIT)(25), and 
anxiety disorders measured using the anxiety item of the Primary Care Evaluation of Mental Disorders (PRIME-
MD) (26). For more detail see appendix. 
 
 
2.5. Statistical analyses 
 
Baseline comparisons were made using descriptive statistics. The assessment of the risk of depression according 
to physical condition was conducted using multivariable logistic regression. The baseline characteristics of missing 
and successfully followed up participants were compared, together with an analysis of the association between 
these characteristics and missing status using the two sided independent t-test for continuous variables and Chi2 
for binary variables to identify predictors of missing data. Sensitivity analyses were conducted to assess the impact 
of missingness on the estimation of the risk of depression. 
  
 
For multivariable analyses odds ratios and 95% confidence intervals are reported. All analyses were conducted 
using Stata 12(21). 
 
3. RESULTS 
 
3.1. Descriptive results 
 
Baseline characteristics of healthy participants and of the participants with the most prevalent diagnostic groups 
are displayed in Table 1. Quality of life (QoL) associated with physical health was low in those with autoimmune 
disorders, osteoarthritis, neurological and cerebrovascular disorders, but QoL associated with mental health was 
low in almost all groups (locomotor pain disorders, functional disorders, osteoarthritis, allergies, migraine, 
autoimmune disorder, endocrine, neurological, and cerebrovascular disorders).  
 
There was a high comorbidity between diagnostic groups as shown in Table 2. It can be seen that no more than 
a third of the participants in each diagnostic group had just one diagnosis. The most frequent comorbid diagnoses 
were metabolic syndrome, cardiovascular disease, and osteoarthritis. 
 
3202 (70%) of patients who were not depressed at baseline were successfully followed up at six months and 3015 
(66%) at 12 months (see Figure 1).  After one year follow up, the cumulative incidence of depression in the total 
sample was 12% (321 new cases out of 2787 successfully followed up participants). The cumulative incidence of 
depression was 10% (124/1264) in healthy participants and 13% in participants with chronic physical conditions 
(197/1523). The incidence of depression in the autoimmune group was 20% (12/61). 
 
3.2. Risk of depression 
 
 
The odds of depression were higher for all inflammatory illnesses before and after adjustment for confounders 
(Table 3). Most non-inflammatory illnesses showed no increased odds of depression, except for locomotor pain 
  
disorders (OR 2.24 95%CI 1.36 -3.71), but this association was not statistically significant after adjustment for 
confounders (OR 1.57 95% CI 0.84 -2.92). 
 
We conducted a supplementary stepwise analysis (data not shown) to examine the increasing odds for depression 
in the cardiovascular group with adjustment. When we entered gender into the model no significant change 
occurred in the odds of depression (OR 1.35 95% CI 1.01 - 1.81), but when we added age a significant rise in the 
odds of depression occurred (OR 1.79 95% CI 1.25 - 2.56). Neither the point estimate nor the 95% confidence 
intervals changed after the addition of the remaining confounders. 
 
Risk of depression rose with increasing inflammatory load, with higher odds of depression in the autoimmune than 
cardio-metabolic group, and both had higher odds of depression than the non-inflammatory group. After 
adjustment for illness load, the odds of depression still showed an increase with increasing inflammatory, but this 
finding was no longer statistically significant. The only group that had a significantly higher odds of depression 
after adjustment for illness load was the autoimmune disorder group (OR 2.43, 95%CI 1.05 - 5.63) (Table 4, a). 
 
In order to test whether comorbidity and illness load had a greater impact on risk of depression in the presence of 
inflammation, we stratified by comorbidity within the inflammatory illness group (Table 4, b). The regression model 
estimated that the odds of depression increased with inflammatory load. The highest odds of depression was 
associated with the presence of autoimmune disorders plus any other inflammatory disorder, which is our best 
proxy for a very high inflammatory state (OR 6.52, 95% CI 2.14 - 19.83). Similarly, the odds of depression in the 
groups with three or more cardio-metabolic disorders was higher than the odds where there was one cardio-
metabolic disorder (OR 2.38, 95% CI 1.22 - 4.61 for more than three cardio-metabolic disorders versus an OR of 
1.28, 95% CI 0.84 -1.97 for one cardio-metabolic disorder). 
 
3.3. Missingness 
 
We examined the people with missing data on depression at one or both of the two follow up interviews. A baseline 
comparison of participants lost to follow up versus those successfully followed up, showed that the follow-up data 
were missing at random (see Appendix, Table 5). The pattern of missing data at baseline and each follow-up were 
as follows: no depression/missing/missing=1151 participants, no depression/missing/no depression=234 
  
participants, and no depression/no depression/missing=397 participants. Considering that data were missing at 
random and that covariates predicting missingness were included in the adjusted model, we undertook a complete 
case analysis. However, in a sensitivity analysis we assumed that all missing were either depressed or not 
depressed.  In the first scenario, assuming missing participants as non-depressed (Appendix, Table 6), the 
cumulative incidence of depression decreased from 11.5% to 7.0%. Nevertheless, the influence of illness category 
remained significant and followed the same increasing risk with illness category seen in the complete case 
analysis. In the second scenario when all missing were assigned a diagnosis of depression, the cumulative 
incidence rates rose to 22.6%, 27.9%, and 46.0% respectively (Appendix, Table 7) and the associations with 
inflammation lost statistical significance.   
 
4. DISCUSSION 
 
The results of this secondary analysis of the predictD-Spain cohort study provides evidence for a higher risk of 
depression among people with physical illnesses characterized by systemic inflammation than in those with non-
inflammatory illnesses.  Both load and type of illness impacted in a different manner upon the risk of depression, 
for example in the risk of depression conferred by comorbid cardio-metabolic versus autoimmune disorders. 
Hence, the assessment of physical illness as a risk factor for depression should take account of at least the type 
of comorbidity and number of illnesses involved.  
 
The role of inflammation in major depression suggests new alternatives for treatment, especially in medically ill 
people. For instance, in a retrospective cohort study, Pasco et al found that both statins and aspirin are protective 
factors for depression (hazard ratios for depression = 0.20, 95% CI 0.04-0.85) (22) in a population of long term 
users of these medications. A recently published meta-analysis of randomized controlled trials (23) concerning the 
role of anti-inflammatory medications in depression and depressive symptoms concluded that non-steroidal anti-
inflammatory drugs (NSAIDs) had a significant impact upon both depressive symptoms and remission of a major 
depressive episode. It is important to note that the exact nature of the physical health of the participants included 
in the studies was not clear, and there was only one study using healthy individuals. Thus we have little evidence 
of the effectiveness of NSAIDs or cytokine inhibitors in individuals with no physical illness, and it is not clear which 
specific clinical population might benefit from them. The role of anti-inflammatory drugs in depressive symptoms 
  
may be relevant only in populations suffering physical illnesses with an underlying inflammatory pathophysiology 
but, again, such a hypothesis has yet to be tested. 
 
There are important limitations to consider in the interpretation of the findings. Firstly, we had to depend upon the 
variables that were available in the predictD-Spain data, thus excluding from the analysis risk factors that are 
relevant for the assessment of the illness-depression relationship, such as exercise, diet, and smoking behaviour. 
With regard to the latter, whilst it was taken into account in the predictD-study, the Spanish data had considerable 
missing data. Thus it was not possible to include it in our models. Secondly, the estimation of exposure to 
inflammation was assumed to be present according to diagnosis, without information about the level of 
inflammation, duration of exposure, severity of the illness, prognosis, and current treatment.  One of the objectives 
of this study was to examine the role of inflammation in the context of diagnosis and comorbidity. However, in the 
absence of biological markers, interpretation of the role of inflammation remains theoretical, and we acknowledge 
this as a limitation to the interpretation of our results. Future studies should incorporate both biological markers 
and diagnostic criteria (such as ICD-10 or ICPC-2) to improve internal validity without compromising the 
generalizability of the findings. Moreover, the assessment of the impact of physical illness on the risk of depression 
should incorporate an comprehensive assessment of health, including disease diagnostic criteria, behavioural 
health factors and biological markers.  A simple binary assessment of the presence or absence of any physical 
illness is likely to underestimate the impact that physical health has on psychiatric outcomes. 
 
One of the strengths of this study is that the results are highly generalizable. The diagnoses were retrieved from 
the GPs’ records using an internationally validated codification for physical illness, therefore increasing the 
comparability of these results with findings from other studies. With regard to internal validity, missingness was 
examined in detail and handled appropriately, thus providing robust evidence for the estimation of the outcome.  
 
To our knowledge, this is the first prospective study to test the inflammatory hypothesis of depression, which uses 
diagnosis as a proxy for exposure to systemic inflammation, and considers the role of comorbidity in the impact of 
physical health on incidence of depression. Our results provide clinically relevant information about how the risk 
of depression varies according to type of illness and comorbidity, and suggest new research strategies for the 
assessment of illness as a risk factor for depression.   
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